229 related articles for article (PubMed ID: 18392344)
1. Risk factors and clinical presentation of venous thromboembolism according to the age of relatives of patients with factor V Leiden.
Couturaud F; Leroyer C; Mottier D;
Thromb Haemost; 2008 Apr; 99(4):793-4. PubMed ID: 18392344
[No Abstract] [Full Text] [Related]
2. Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.
Couturaud F; Duchemin J; Leroyer C; Delahousse B; Abgrall JF; Mottier D;
Thromb Haemost; 2008 Jan; 99(1):223-8. PubMed ID: 18217158
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
Strandberg K; Svensson PJ; Ohlin AK
Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
[TBL] [Abstract][Full Text] [Related]
4. Hereditary thrombophilic risk factors and venous thromboembolism in Istanbul, Turkey: the role in different clinical manifestations of venous thromboembolism.
Okumus G; Kiyan E; Arseven O; Tabak L; Diz-Kucukkaya R; Unlucerci Y; Abaci N; Unaltuna NE; Issever H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):168-73. PubMed ID: 17895505
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of patients with factor V Leiden or prothrombin G20210A and a first episode of venous thromboembolism. Findings from the RIETE Registry.
Gadelha T; Roldán V; Lecumberri R; Trujillo-Santos J; del Campo R; Poggio R; Monreal M;
Thromb Res; 2010 Oct; 126(4):283-6. PubMed ID: 20627204
[TBL] [Abstract][Full Text] [Related]
6. Factor V Leiden: a case study and review.
Slusher KB
Dimens Crit Care Nurs; 2010; 29(1):6-10. PubMed ID: 20010186
[TBL] [Abstract][Full Text] [Related]
7. Factor V Leiden mutation and pregnancy-related complications.
Kjellberg U; van Rooijen M; Bremme K; Hellgren M
Am J Obstet Gynecol; 2010 Nov; 203(5):469.e1-8. PubMed ID: 21055512
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of thrombophilia testing in venous thromboembolic disease: findings from the RIETE registry.
Gabriel F; Portolés O; Labiós M; Rodríguez C; Cisneros E; Vela J; Nuñez M;
Clin Appl Thromb Hemost; 2013; 19(1):42-7. PubMed ID: 22327823
[TBL] [Abstract][Full Text] [Related]
9. Thrombophilia in liver disease.
Kittisupamongkol W
Am J Gastroenterol; 2009 Jun; 104(6):1604. PubMed ID: 19491882
[No Abstract] [Full Text] [Related]
10. Thrombophilia and gestational VTE.
Simioni P
Thromb Res; 2009; 123 Suppl 2():S41-4. PubMed ID: 19217475
[No Abstract] [Full Text] [Related]
11. Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
Chaireti R; Jennersjö C; Lindahl TL
Thromb Res; 2009 Jun; 124(2):178-84. PubMed ID: 19232683
[TBL] [Abstract][Full Text] [Related]
12. High factor VIII activity, high plasminogen activator inhibitor 1 antigen levels and low factor XII activity contribute to a thrombophilic tendency in elderly venous thromboembolism patients.
Gary T; Hafner F; Froehlich H; Stojakovic T; Scharnagl H; Pilger E; Brodmann M
Acta Haematol; 2010; 124(4):214-7. PubMed ID: 21071930
[No Abstract] [Full Text] [Related]
13. Fibrinogen Aalpha-Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolism.
Le Gal G; Delahousse B; Lacut K; Malaviolle V; Regina S; Blouch MT; Couturaud F; Mottier D; Oger E; Gruel Y;
Thromb Res; 2007; 121(3):333-8. PubMed ID: 17568659
[TBL] [Abstract][Full Text] [Related]
14. Minor injuries as a risk factor for venous thrombosis.
van Stralen KJ; Rosendaal FR; Doggen CJ
Arch Intern Med; 2008 Jan; 168(1):21-6. PubMed ID: 18195191
[TBL] [Abstract][Full Text] [Related]
15. Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study.
Folkeringa N; Korteweg FJ; Veeger NJ; Middeldorp S; Hamulyak K; Prins MH; Erwich JJ; Büller HR; van der Meer J
Thromb Res; 2009; 123(3):511-4. PubMed ID: 18455758
[No Abstract] [Full Text] [Related]
16. Factor V Leiden: how great is the risk of venous thromboembolism?
Shaheen K; Alraies MC; Alraiyes AH; Christie R
Cleve Clin J Med; 2012 Apr; 79(4):265-72. PubMed ID: 22473726
[TBL] [Abstract][Full Text] [Related]
17. Hormone therapy and raloxifene reduce the coagulation inhibitor potential.
Andresen MS; Eilertsen AL; Abildgaard U; Sandset PM
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):455-60. PubMed ID: 17581320
[TBL] [Abstract][Full Text] [Related]
18. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia.
Wichers IM; Tanck MW; Meijers JC; Lisman T; Reitsma PH; Rosendaal FR; Büller HR; Middeldorp S
Thromb Haemost; 2009 Mar; 101(3):465-70. PubMed ID: 19277406
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of factor V Leiden and prothrombin G20210A gene mutation.
Al-Aama JY
Saudi Med J; 2005 Nov; 26(11):1844. PubMed ID: 16311688
[No Abstract] [Full Text] [Related]
20. Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER study.
Canonico M; Olié V; Carcaillon L; Tubert-Bitter P; Scarabin PY;
Thromb Haemost; 2008 Jan; 99(1):246-8. PubMed ID: 18217166
[No Abstract] [Full Text] [Related]
[Next] [New Search]
